Medical Data Collection for the Evaluation of Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine
Recruiting
- Conditions
- Metastatic Malignant Neoplasm in the Spine
- Interventions
- Other: Electronic Health Record Review
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 500
- Registration Number
- NCT04751422
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- Drug: DS-1594bDrug: AzacitidineDrug: CyclophosphamideDrug: PosaconazoleDrug: VenetoclaxDrug: CytarabineDrug: VoriconazoleDrug: DexamethasoneBiological: FilgrastimDrug: LeucovorinDrug: MesnaDrug: MethotrexateDrug: PrednisoneBiological: RituximabDrug: Vincristine
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
Phase 2
Recruiting
- Conditions
- Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8
- Interventions
- Procedure: Chest RadiographyProcedure: Computed TomographyProcedure: Follow-UpProcedure: Imaging TechniqueOther: Questionnaire Administration
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 227
- Registration Number
- NCT04751409
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Recruiting
- Conditions
- Crohn DiseaseAutoimmune DiseasePsoriasisUlcerative ColitisAnkylosing SpondylitisEnteropathic ArthritisEnteropathic SpondylitisInflammatory Bowel DiseaseReactive ArthritisSystemic Lupus Erythematosus
- Interventions
- Other: Educational InterventionOther: Best PracticeOther: Questionnaire AdministrationOther: InterviewOther: Survey Administration
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 125
- Registration Number
- NCT04751396
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04746235
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
Phase 4
Recruiting
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmTumor Lysis Syndrome
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04745910
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
Phase 2
Recruiting
- Conditions
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Interventions
- Drug: Brentuximab VedotinDrug: CyclophosphamideDrug: DoxorubicinBiological: NivolumabDrug: PrednisoneOther: Quality-of-Life AssessmentBiological: Rituximab
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT04745949
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes
Recruiting
- Conditions
- DepressionGenetic DisorderHematopoietic and Lymphoid Cell NeoplasmAnxiety DisorderMalignant Solid Neoplasm
- Interventions
- Other: Electronic Health Record Review
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 700000
- Registration Number
- NCT04743466
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
Early Phase 1
Completed
- Conditions
- Malignant Solid NeoplasmSymptomatic COVID-19 Infection Laboratory-ConfirmedHematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Biological: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04742595
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Early Phase 1
Recruiting
- Conditions
- Steroid Refractory Graft Versus Host DiseaseHematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Other: Cellular TherapyDrug: Ruxolitinib
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04744116
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath